---
title: "InMed Pharmaceuticals (INM) news: going concern and offering"
url: "https://aibio.space/companies/inmed-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "INM going concern, offering, Nasdaq notice and merger news: InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business."
---

INM InMed Pharmaceuticals Inc. NASDAQ · Canada

# InMed Pharmaceuticals (INM) news INM going concern, offering and Nasdaq notice news

Mergers · 2026-10-27

## [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/)

Holders of record on November 5, 2026 would get one CVR per share, but only if shareholders approve a return of capital proposal on November 4. The company had $2.2 million in cash at June 30, 2026.

## Latest InMed Pharmaceuticals news

1. 2026-09-18 Listings [InMed receives Nasdaq notice on minimum shareholders' equity](https://aibio.space/news/inmed-receives-nasdaq-notice-minimum-shareholders-equity/) Shareholders' equity of $1,075,007 in the 10-K for the year ended June 30, 2026 fell below the $2,500,000 Nasdaq minimum. The company has 45 calendar days to submit a plan.
2. 2026-05-19 Mergers [InMed agrees to all-stock merger with Mentari Therapeutics](https://aibio.space/news/inmed-agrees-all-stock-merger-mentari-therapeutics/) InMed and privately held Mentari Therapeutics signed a definitive merger agreement, alongside a concurrent US$290 million private placement for the combined company.
3. 2026-05-06 Company Updates [InMed reports third quarter results and a $3.0 million net loss](https://aibio.space/news/inmed-reports-third-quarter-results-3-0-million-net-loss/) InMed reported a net loss of $3.0 million for the quarter ended March 31, 2026, and cash, cash equivalents and short-term investments of $5.2 million, as it winds down its commercial operations.
4. 2026-04-27 Financings [InMed cuts exercise price on preferred investment options to $0.80](https://aibio.space/news/inmed-cuts-exercise-price-preferred-investment-options-0-80/) InMed agreed to amend the exercise prices on preferred investment options held by Sabby Volatility Warrant Master Fund, Ltd. and affiliates of H.C. Wainwright & Co., LLC to $0.80 per share.
5. 2026-03-30 Listings [InMed Pharmaceuticals gets Nasdaq minimum bid price deficiency notice](https://aibio.space/news/inmed-pharmaceuticals-gets-nasdaq-minimum-bid-price-deficiency-notice/) Nasdaq told InMed on March 27, 2026 that its shares closed below $1.00 for 30 consecutive trading days. The company has 180 calendar days to regain compliance and keeps trading as INM.
6. 2026-03-06 Distress [InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business](https://aibio.space/news/inmed-pharmaceuticals-wind-down-baymedica-only-revenue-generating/) InMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.
7. 2025-06-30 Financings [InMed Pharmaceuticals agrees to sell shares at $2.561 in $5 million private placement](https://aibio.space/news/inmed-pharmaceuticals-agrees-sell-shares-2-561-5-million-private/) A single institutional investor is buying 1,952,363 shares or pre-funded warrants plus options on the same number of shares. H.C. Wainwright is placement agent.

## InMed Pharmaceuticals at a glance

- **Ticker**: INM

- **Listing**: NASDAQ

- **Country**: Canada

- **Cash, Jun 30, 2026**: $2.2 million

### Related companies

- [BetterLife Pharma](https://aibio.space/companies/betterlife-pharma/) CSE: BETR
- [Milestone Pharmaceuticals](https://aibio.space/companies/milestone-pharmaceuticals/) NASDAQ: MIST
- [NORTH BUD FARMS INC](https://aibio.space/companies/north-bud-farms/) OTC: NOBDF
- [Nurexone Biologic](https://aibio.space/companies/nurexone-biologic/) TSXV: NRX
- [Arch Biopartners](https://aibio.space/companies/arch-biopartners/) TSXV: ARCH
- [Mindbio Therapeutics](https://aibio.space/companies/mindbio-therapeutics/) CSE: MBIO
- [ABATTIS BIOCEUTICALS CORP](https://aibio.space/companies/abattis-bioceuticals/) OTC: ATTBF
- [Marvel Biosciences](https://aibio.space/companies/marvel-biosciences/) TSXV: MRVL

### Also on NASDAQ

- [Zhengye Biotechnology Holding](https://aibio.space/companies/zhengye-biotechnology/) ZYBT
- [Champions Oncology](https://aibio.space/companies/champions-oncology/) CSBR
- [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) XLO
- [Estrella Immunopharma](https://aibio.space/companies/estrella-immunopharma/) ESLA
- [uniQure](https://aibio.space/companies/uniqure-n-v/) QURE
- [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) SNWV

## What InMed Pharmaceuticals does

InMed Pharmaceuticals Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the CB1 and CB2 cannabinoid receptors, as well as other receptor targets linked to human disease. On March 4, 2026, its board approved winding down BayMedica's commercial operations, the only revenue-generating business of the company, and BayMedica had wound down all operating activities by June 30, 2026. The remaining work is preclinical development of three product candidates. INM-901 is a candidate for Alzheimer's disease, where the company reports reduced neuroinflammation in preclinical models and has a pre-IND meeting with the FDA scheduled for the third quarter of calendar 2026. INM-089 is being developed for dry age-related macular degeneration. The company has also completed a Phase 2 trial of INM-755 (cannabinol) cream for epidermolysis bullosa, which showed enhanced anti-itch activity compared with a control cream. The text says these priorities apply if a merger is not consummated, and that further development requires additional financing. As of September 1, 2026, the company had 6 full-time employees.

| Product or program | What it is | Stage |
|---|---|---|
| INM-901 | Small molecule candidate for Alzheimer's disease that reduces neuroinflammation | Preclinical; pre-IND meeting scheduled for third quarter of calendar 2026 |
| INM-089 | Candidate for dry age-related macular degeneration with neuroprotective effects | Preclinical |
| INM-755 (cannabinol) cream | Topical cream for symptoms related to epidermolysis bullosa | Phase 2 clinical trial completed |

Summarised from the company's [10-K filed Sep 9, 2026](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/ea0301263-10k_inmed.htm).

## InMed Pharmaceuticals annual financials

| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue |  | [$4.9 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390025090210/) |
| Research and development | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) |
| Net income (loss) | [-$12.6 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) |
| Cash from operations | [-$8.6 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) | [-$8.1 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) |
| Cash and equivalents | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) | [$10.7 million](https://www.sec.gov/Archives/edgar/data/1728328/000121390026052920/) |
| Short-term investments | [$39,670](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) | [$43,384](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/) |

Latest balance sheet, Jun 30, 2026 (10-K): cash and equivalents $2.2 million, plus short-term investments of $39,670, $2.2 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about InMed Pharmaceuticals

Has InMed Pharmaceuticals issued a going-concern warning?

Our latest story on this, dated Mar 6, 2026: "InMed Pharmaceuticals to wind down BayMedica, its only revenue-generating business". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmed-pharmaceuticals-wind-down-baymedica-only-revenue-generating/).

Has InMed Pharmaceuticals raised money recently?

Our latest story on this, dated May 19, 2026: "InMed agrees to all-stock merger with Mentari Therapeutics". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmed-agrees-all-stock-merger-mentari-therapeutics/).

Has InMed Pharmaceuticals received a Nasdaq deficiency notice?

Our latest story on this, dated Sep 18, 2026: "InMed receives Nasdaq notice on minimum shareholders' equity". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmed-receives-nasdaq-notice-minimum-shareholders-equity/).

Is InMed Pharmaceuticals involved in a merger or acquisition?

Our latest story on this, dated Oct 27, 2026: "InMed sets November 5 record date for CVRs tied to Mentari merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/).

What is the ticker symbol of InMed Pharmaceuticals?

InMed Pharmaceuticals Inc. trades under the ticker INM on NASDAQ.

Where is InMed Pharmaceuticals listed?

InMed Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MWG.

What is the SEC CIK of InMed Pharmaceuticals?

The SEC Central Index Key (CIK) for InMed Pharmaceuticals Inc. is 1728328. Its filings are on SEC EDGAR.

How many shares does InMed Pharmaceuticals have outstanding?

5,493,735 shares as of 2026-09-02, per the cover page of its 10-K filed 2026-09-09.

Which country or territory is InMed Pharmaceuticals listed under?

Our directory records InMed Pharmaceuticals Inc. under Canada.

What does InMed Pharmaceuticals do?

Our directory classifies InMed Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of InMed Pharmaceuticals?

The ISIN recorded for InMed Pharmaceuticals Inc. is CA4576377002.

Does aibio.space cover InMed Pharmaceuticals?

aibio.space lists InMed Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is InMed Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as A1.

What does InMed Pharmaceuticals develop?

InMed Pharmaceuticals Inc. is a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the CB1 and CB2 cannabinoid receptors, as well as other receptor targets linked to human disease. On March 4, 2026, its board approved winding down BayMedica's commercial operations, the only revenue-generating business of the company, and BayMedica had wound down all operating activities by June 30, 2026.

What is INM-901 from InMed Pharmaceuticals?

INM-901: Small molecule candidate for Alzheimer's disease that reduces neuroinflammation Stage: Preclinical; pre-IND meeting scheduled for third quarter of calendar 2026.

## Investor discussion: InMed Pharmaceuticals

Members talk about InMed Pharmaceuticals (INM). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at InMed Pharmaceuticals, newest first. Each line links the filing it comes from.

1. 2026-10-27 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1728328/000119312526432362/d128958d425.htm)
2. 2026-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/ea030576901ex99-1.htm)
3. 2026-09-09 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/ea0301263-10k_inmed.htm)
4. 2026-06-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000106299326003132/exhibit99-1.htm)
5. 2026-05-19 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000106299326002787/exhibit99-1.htm)
6. 2026-05-19 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea029148201ex99-1.htm)
7. 2026-04-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390026039938/ea0284976-424b5_inmed.htm)
8. 2026-03-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000106299326001697/exhibit99-1.htm)
9. 2026-03-06 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390026024752/ea027986901ex99-1.htm)
10. 2025-06-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390025059673/ea024747601ex99-1_inmed.htm)
11. 2025-06-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,4.01,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390025054315/ea0245506-8k_inmed.htm)
12. 2025-02-13 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390025013204/ea023095101ex99-1_inmed.htm)
13. 2024-12-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390024110429/ea022531101ex99-1_inmed.htm)
14. 2024-12-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390024109891/ea022502201ex99-1_inmed.htm)
15. 2024-11-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390024096025/ea022057801ex99-1_inmed.htm)
16. 2024-11-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/ea022002901ex99-1_inmed.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:INM on TradingView](https://www.tradingview.com/symbols/NASDAQ-INM/).

## SEC filings and registration

- **SEC name**: InMed Pharmaceuticals Inc.

- **CIK**: 1728328

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: INM (Nasdaq)

- **State or country of incorporation**: A1

- **Fiscal year ends**: June 30

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: C/O NORTON ROSE FULBRIGHT CANADA LLP, VANCOUVER, V6B 0M3

- **Phone**: (604) 669-7207

- **Shares outstanding**: 5,493,735 as of 2026-09-02 (10-K filed 2026-09-09)

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/ea0305769-8k_inmed.htm) filed 2026-09-18
- [10-K](https://www.sec.gov/Archives/edgar/data/1728328/000121390026098419/ea0301263-10k_inmed.htm) filed 2026-09-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/ea0298644-8k425_inmed.htm) filed 2026-07-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000121390026077127/ea0297284-8k425_inmed.htm) filed 2026-07-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000106299326003132/form8k.htm) filed 2026-06-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000121390026058795/ea0291482-8k425_inmed.htm) filed 2026-05-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000106299326002787/form8k.htm) filed 2026-05-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/form8k.htm) filed 2026-05-07

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001728328), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

InMed Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker INM, recorded under Canada. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: InMed Pharmaceuticals Inc.

- **Ticker**: INM

- **Listing**: NASDAQ

- **Country or territory**: Canada

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: CA4576377002

- **Other listed symbols**: GETTEX:MWG

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-INM/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/inmed-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "InMed Pharmaceuticals (INM) news: going concern and offering", 2026-10-31, https://aibio.space/companies/inmed-pharmaceuticals/